Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2beta-Thalassemia 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 189Magnetic Resonance Spectroscopy 150pembrolizumab 147Carboplatin 110Biopsy 106Cyclophosphamide 92Cisplatin 85Paclitaxel 76Bevacizumab 68Gemcitabine 67Nivolumab 59fludarabine 56Fluorouracil 52Radiotherapy 49Capecitabine 49Pemetrexed 45Dexamethasone 45Oxaliplatin 44Rituximab 43Leucovorin 43atezolizumab 42Docetaxel 41venetoclax 39Doxorubicin 39durvalumab 37Temozolomide 32Standard of Care 32Radiation 32Prednisone 32Cetuximab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × luspatercept × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡